- [JP Morgan] Participating in a conference from January 13-16 with back-to-back business meetings with leading international companies - Highlighting technology export discussions for 'ID110521156', an oral synthetic GLP-1 agonist [by Lee, Young Sung] The management team of Ildong Pharmaceutical Group is set to participate in the 'JP Morgan Healthcare Conference 2025 (hereinafter referred to as the JP Morgan Conference),' scheduled to take place in San Francisco, USA, from January 13 to 16 (local time)
Topical treatment of diabetic foot ulcers using a novel quercetin-loaded hyaluosome gel nanoformulation
Authentic filler only: The clinic must use genuine, Thai FDAapproved fillers with visible registration numbers, and open the box in front of you while showing the barcode to confirm authenticity before injection
[2] [3] Additionally, because the compound promotes blood vessel formation (angiogenesis), there are theoretical concerns about potential cancer promotion that require further investigation
24 FanningS.HaqueA.ImberdisT.BaruV.BarrasaM
Weight continues declining through week 48 and beyond based on Phase 3 trial data
